In patients with binge eating disorder, clinical and treatment responses to lisdexamfetamine dimesylate (LDX) were found to be similar across age and sex, according to study results published in the Journal of Clinical Psychiatry.
Researchers conducted a post hoc analysis using data from 2 separate studies that evaluated the use of LDX in patients with binge eating disorder. The pooled safety analysis set included 745 participants, and the full analysis set comprised 724 participants. The analysis pooled data on sex (men, n=105 and n=97; women, n=640 and n=627, respectively) and age (<40 years, n=398 and n=386; ≥ 40 years, n=347 and n=338, respectively) and compared clinical parameters and responses across these groups. The specific endpoints evaluated were efficacy and safety of LDX treatment.
After analysis, the researchers found that clinical characteristics (body mass index, racial distribution, and age) of patients did not vary on the basis of age or sex, with the exclusion of males weighing more than females. With respect to efficacy, treatment with LDX was marginally superior to placebo, assessed using the mean number of binge eating days per week and the Yale-Brown Obsessive Compulsive Scale Modified for Binge Eating total score.
With respect to safety, LDX therapy in both groups was associated with an increased frequency of treatment-related adverse events compared with placebo.
Although this study focused on sex and age, researchers noted that future studies might examine such factors as the duration of the binge eating disorder diagnosis or of race or ethnicity on binge eating disorder characteristics and treatment response.
Kornstein SG, Bliss C, Kando J, Madhoo M. Clinical characteristics and treatment response to lisdexamfetamine dimesylate versus placebo in adults with binge eating disorder: analysis by gender and age. J Clin Psychiatry. 2019;80(2):18m12378.